{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:54:28Z","timestamp":1791258868139,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72074142"],"award-info":[{"award-number":["72074142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jval.2026.03.2248","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:07:10Z","timestamp":1777360030000},"page":"1896-1916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modeling Approaches to the Economic Evaluation of Microelimination Strategies for Hepatitis C Virus in High-Risk Populations"],"prefix":"10.1016","volume":"29","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijie","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2026.03.2248_bib2","series-title":"The elimination of hepatitis: a goal for 2030","author":"Clare","year":"2021"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib4","article-title":"Polaris Observatory\u2014supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis","volume":"27","author":"Razavi","year":"2022","journal-title":"Antivir Ther"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: an updated analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jval.2026.03.2248_bib6","series-title":"Epidemiology, Prevention and Elimination","first-page":"247","article-title":"Micro-elimination: A key component of global hepatitis C elimination","volume":"1","author":"Lazarus","year":"2021"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations","volume":"38","author":"Lazarus","year":"2018","journal-title":"Semin Liver Dis"},{"issue":"Suppl 3","key":"10.1016\/j.jval.2026.03.2248_bib8","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/infdis\/jiac446","article-title":"HCV microelimination for high-risk special populations","volume":"228","author":"Huang","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2026.03.2248_bib9","author":"Dean"},{"issue":"02","key":"10.1016\/j.jval.2026.03.2248_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/a-1777-6112","article-title":"A global systematic review of hepatitis C elimination efforts through micro-elimination","volume":"42","author":"Lazarus","year":"2022","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jval.2026.03.2248_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtbi.2018.11.013","article-title":"Mathematical modeling of hepatitis C virus (HCV) prevention among people who inject drugs: a review of the literature and insights for elimination strategies","volume":"481","author":"Pitcher","year":"2019","journal-title":"J Theor Biol"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2248_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145022","article-title":"Cost-effectiveness of HBV and HCV screening strategies \u2013 A systematic review of existing modelling techniques","volume":"10","author":"Geue","year":"2015","journal-title":"PLOS One"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2248_bib13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000179","article-title":"The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention","volume":"10","author":"Martin","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/jvh.12337","article-title":"Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review","volume":"22","author":"Cousien","year":"2015","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2248_bib15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40273-015-0373-9","article-title":"Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals","volume":"34","author":"Chhatwal","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40273-022-01225-8","article-title":"Best practices: a collection of systematic critical reviews of modeling approaches in specific disease areas","volume":"41","author":"Caro","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2248_bib19","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/add.14731","article-title":"Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs","volume":"114","author":"Barbosa","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2026.03.2248_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.drugpo.2019.05.010","article-title":"Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV\/hepatitis C co-infection who inject opioids","volume":"72","author":"Barocas","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"10","key":"10.1016\/j.jval.2026.03.2248_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003239","article-title":"Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: a model-based analysis","volume":"17","author":"Bernard","year":"2020","journal-title":"PLOS Med"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2248_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26035","article-title":"Cost-effectiveness of hepatitis C virus test-and-treat and risk reduction strategies among men who have sex with men living with HIV in France","volume":"25","author":"Castry","year":"2022","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40121-024-01084-0","article-title":"Achieving Hepatitis C micro-elimination in Chinese injecting drug users: a dynamic network modeling study","volume":"14","author":"Chen","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"10","key":"10.1016\/j.jval.2026.03.2248_bib24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jvh.12919","article-title":"Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: the case of France","volume":"25","author":"Cousien","year":"2018","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52564-0","article-title":"Improved health outcomes from hepatitis C treatment scale-up in Spain\u2019s prisons: a cost-effectiveness study","volume":"9","author":"Dalgic","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jval.2026.03.2248_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.102613","article-title":"Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in people who use injecting drugs in Senegal","volume":"75","author":"Duchesne","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2248_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph22040509","article-title":"Cost-effectiveness of screening and treating chronic hepatitis C virus infection in Zimbabwe","volume":"22","author":"Dzingirai","year":"2025","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/add.13195","article-title":"Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada","volume":"111","author":"Enns","year":"2016","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/jvh.13023","article-title":"Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: a cost-effectiveness analysis","volume":"26","author":"Girardin","year":"2019","journal-title":"J Viral Hepat"},{"issue":"11","key":"10.1016\/j.jval.2026.03.2248_bib30","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/cid\/ciz088","article-title":"Modelling the impact and cost-effectiveness of extended screening and treatment with direct-acting antivirals in a Swiss custodial setting","volume":"69","author":"Girardin","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jval.2026.03.2248_bib31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/cid\/ciz384","article-title":"Cost-effectiveness of hepatitis C virus treatment models for people who inject drugs in opioid agonist treatment programs","volume":"70","author":"Gutkind","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2248_bib32","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/add.14849","article-title":"Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation","volume":"115","author":"Hancock","year":"2020","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M15-0617","article-title":"Prevention of hepatitis C by screening and treatment in U.S. Prisons","volume":"164","author":"He","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245288","article-title":"Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan Province, China","volume":"16","author":"Heffernan","year":"2021","journal-title":"PLOS One"},{"key":"10.1016\/j.jval.2026.03.2248_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugpo.2017.07.022","article-title":"Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands","volume":"47","author":"Helsper","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib36","first-page":"137","article-title":"Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree","volume":"27","author":"Ijioma","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.jval.2026.03.2248_bib37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/13696998.2017.1325744","article-title":"Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study","volume":"20","author":"Kenworthy","year":"2017","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib38","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1186\/s12879-019-4524-z","article-title":"Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies","volume":"19","author":"Krauth","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245896","article-title":"Hepatitis C treatment strategies in prisons: a cost-effectiveness analysis","volume":"16","author":"Kwon","year":"2021","journal-title":"PLOS One"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2248_bib40","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1111\/add.16305","article-title":"Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: an economic evaluation of the INTRO-HCV trial","volume":"118","author":"Lim","year":"2023","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy040","article-title":"Intervention packages to reduce the impact of HIV and HCV infections among people who inject drugs in Eastern Europe and Central Asia: a modeling and cost-effectiveness study","volume":"5","author":"Mabileau","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2248_bib42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jvh.13503","article-title":"The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK","volume":"28","author":"Macgregor","year":"2021","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/add.15630","article-title":"An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis","volume":"117","author":"Mafirakureva","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2026.03.2248_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102811","article-title":"Eradicating hepatitis C: are novel screening strategies for people who inject drugs cost-effective?","volume":"82","author":"Manca","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.18176\/resp.00012","article-title":"Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain","volume":"22","author":"Marco","year":"2020","journal-title":"Rev Espa\u00f1ola Sanid Penitenciaria"},{"issue":"10","key":"10.1016\/j.jval.2026.03.2248_bib46","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1111\/add.15456","article-title":"Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico","volume":"116","author":"Marquez","year":"2021","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2248_bib47","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/hep.28497","article-title":"Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis","volume":"63","author":"Martin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2026.03.2248_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103458","article-title":"Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania","volume":"99","author":"Mohamed","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2248_bib49","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1111\/liv.14628","article-title":"Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England","volume":"40","author":"Mohamed","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib50","article-title":"Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: a cost effectiveness modelling study","volume":"7","author":"Mukherjee","year":"2021","journal-title":"J Virus Erad"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib51","first-page":"379","article-title":"Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups","volume":"82","author":"Opstaele","year":"2019","journal-title":"Acta Gastro-enterol Belg"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210179","article-title":"Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men","volume":"14","author":"Popping","year":"2019","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/add.12754","article-title":"Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs","volume":"110","author":"Schackman","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2026.03.2248_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.102634","article-title":"Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: a cost-effectiveness model","volume":"88","author":"Scott","year":"2021","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jval.2026.03.2248_bib55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugpo.2017.07.006","article-title":"Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade","volume":"47","author":"Scott","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/liv.13240","article-title":"The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit","volume":"37","author":"Selvapatt","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad637","article-title":"Scale-up of direct-acting antiviral treatment in prisons is both cost-effective and key to hepatitis C virus elimination","volume":"11","author":"Shih","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jval.2026.03.2248_bib58","article-title":"Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis","volume":"36","author":"Shih","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2248_bib59","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1093\/cid\/ciz726","article-title":"Cost-effectiveness of direct antiviral agents for hepatitis C virus infection and a combined intervention of syringe access and medication-assisted therapy for opioid use disorders in an injection drug use population","volume":"70","author":"Stevens","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jval.2026.03.2248_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207037","article-title":"Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country","volume":"13","author":"Suijkerbuijk","year":"2018","journal-title":"PLOS One"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib61","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/add.14519","article-title":"Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs","volume":"114","author":"Sweeney","year":"2019","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.jval.2026.03.2248_bib62","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15756","article-title":"Cost-effectiveness of universal and targeted hepatitis C virus screening in the United States","volume":"3","author":"Tatar","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jval.2026.03.2248_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2025.104898","article-title":"Impact and cost-effectiveness of interventions to eliminate hepatitis C virus among people who inject drugs in Haiphong, Vietnam","volume":"143","author":"Trickey","year":"2025","journal-title":"Int J Drug Policy"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib64","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/liv.14232","article-title":"Hepatitis C virus elimination in Indonesia: epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning","volume":"40","author":"Trickey","year":"2020","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.jval.2026.03.2248_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163488","article-title":"Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands","volume":"11","author":"van Santen","year":"2016","journal-title":"PLOS One"},{"key":"10.1016\/j.jval.2026.03.2248_bib66","article-title":"Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study","volume":"49","author":"Ward","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jval.2026.03.2248_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103394","article-title":"Cost-effectiveness of mass screening for hepatitis C virus among all inmates in an Irish prison","volume":"96","author":"Ward","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"8","key":"10.1016\/j.jval.2026.03.2248_bib68","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/add.14978","article-title":"Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England","volume":"115","author":"Ward","year":"2020","journal-title":"Addiction"},{"issue":"Suppl 5","key":"10.1016\/j.jval.2026.03.2248_bib69","doi-asserted-by":"crossref","first-page":"v5","DOI":"10.1093\/jac\/dkz451","article-title":"The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK","volume":"74","author":"Ward","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.jval.2026.03.2248_bib70","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jvh.12904","article-title":"Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies","volume":"25","author":"Wisloff","year":"2018","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib71","doi-asserted-by":"crossref","first-page":"E662","DOI":"10.9778\/cmajo.20170048","article-title":"Model-based projection of health and economic effects of screening for hepatitis C in Canada","volume":"5","author":"Wong","year":"2017","journal-title":"CMAJ Open"},{"key":"10.1016\/j.jval.2026.03.2248_bib72","article-title":"The cost-effectiveness of integrating simplified HCV testing into HIV pre-exposure prophylaxis (PrEP) and treatment services among men who have sex with men in Taiwan","volume":"48","author":"Wu","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"issue":"7","key":"10.1016\/j.jval.2026.03.2248_bib73","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.1870","article-title":"Health and economic impact of periodic hepatitis C virus testing among people who inject drugs","volume":"6","author":"Zhu","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2248_bib74","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3018(22)00077-7","article-title":"Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression","volume":"9","author":"Hosseini-Hooshyar","year":"2022","journal-title":"Lancet HIV"},{"issue":"9","key":"10.1016\/j.jval.2026.03.2248_bib75","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1007\/s10461-024-04398-9","article-title":"Examining the effects of PrEP use on sexual behaviors and sexually transmitted infections among Chinese men who have sex with men: a cross-sectional study","volume":"28","author":"She","year":"2024","journal-title":"AIDS Behav"},{"issue":"14","key":"10.1016\/j.jval.2026.03.2248_bib76","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1001\/jama.2019.2947","article-title":"Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection","volume":"321","author":"Traeger","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2026.03.2248_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104185","article-title":"Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark","volume":"121","author":"Demant","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2248_bib78","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.27403","article-title":"The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs","volume":"60","author":"Hellard","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2026.03.2248_bib79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jtbi.2011.12.008","article-title":"Modelling hepatitis C transmission over a social network of injecting drug users","volume":"297","author":"Rolls","year":"2012","journal-title":"J Theor Biol"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib80","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/pam.2114","article-title":"Can we protect drug users from hepatitis C?","volume":"20","author":"Pollack","year":"2001","journal-title":"J Policy Anal Manag"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2248_bib81","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0272989X0102100502","article-title":"Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users","volume":"21","author":"Pollack","year":"2001","journal-title":"Med Decis Mak"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2248_bib82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1012790230000","article-title":"Ignoring \u201cdownstream infection\u201d in the evaluation of harm reduction interventions for injection drug users","volume":"17","author":"Pollack","year":"2001","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"10.1016\/j.jval.2026.03.2248_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078286","article-title":"Hepatitis C transmission and treatment in contact networks of people who inject drugs","volume":"8","author":"Rolls","year":"2013","journal-title":"PLOS One"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2248_bib84","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.drugpo.2006.02.008","article-title":"Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention","volume":"17","author":"Hutchinson","year":"2006","journal-title":"Int J Drug Policy"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib85","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41598-017-01862-6","article-title":"Impact of hepatitis C Treatment as Prevention for People Who Inject Drugs is sensitive to contact network structure","volume":"7","author":"Metzig","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2248_bib86","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","article-title":"Using cost-effectiveness analysis to address health equity concerns","volume":"20","author":"Cookson","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2248_bib87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0272989X15583266","article-title":"Distributional cost-effectiveness analysis: a tutorial","volume":"36","author":"Asaria","year":"2016","journal-title":"Med Decis Mak"},{"issue":"8","key":"10.1016\/j.jval.2026.03.2248_bib90","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jval.2023.04.004","article-title":"Developing criteria for health economic quality evaluation tool","volume":"26","author":"Kim","year":"2023","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152602396X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152602396X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:45:01Z","timestamp":1791258301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152602396X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":85,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S109830152602396X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2248","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling Approaches to the Economic Evaluation of Microelimination Strategies for Hepatitis C Virus in High-Risk Populations","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}